Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers,Welcome to the latest issue of Microb
The World Health Organization says it has cleared the Pfizer-BioNTech coronavirus vaccine for emergency use, meaning poorer countries may soon get access to the shooter already available in Europe and North America.
Every country which has a drug regulatory agency will need to issue its own approval for any COVID-19 vaccine, but states with weak systems usually rely on WHO to vet the shots.
The international body said late Thursday that the decision to issue its first emergency use validation for a COVID-19 vaccine”opens the door for countries to expedite their own regulatory approval processes to administer and import the vaccine.”
The UN health agency said its inspection found the Pfizer-BioNTech vaccine, which has already received clearance in the United States, Britain, the European Union and a dozen other nations,”fulfilled the must-have criteria for efficacy and safety set from WHO.”
The BioNTech-Pfizer vaccine has to be kept at ultra-frozen temperatures, a big hurdle for developing countries where the essential freezers and reliable electricity supply may not be available.
“This requirement makes the vaccine harder to deploy in settings where ultra-cold chain equipment may not be available or accessible,” WHO said, adding that it was”working to support countries in assessing their delivery plans and preparing for use where possible”.
